Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SuFEx and macrocyclic chelation define orthogonal reactivity domains enabling isotopically versatile radiopharmaceuticals from a single peptide precursor.

bioRxiv : the preprint server for biology·2026
Same author

Urine-derived stem cell extracellular vesicles promote recovery from acute kidney injury in mice and human kidney organoids.

American journal of physiology. Renal physiology·2026
Same author

Erratum: Efficient kidney gene transfer and proximal tubule transduction using self-complementary AAV.cc47 vectors.

Molecular therapy. Advances·2026
Same author

PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden-Driven Variability.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma.

Science advances·2026
Same author

Tracking of Urine-Derived Stem Cells in Mice.

Methods in molecular biology (Clifton, N.J.)·2025
Same journal

Overall Survival with [<sup>177</sup>Lu]Lu-PSMA-617 Versus [<sup>177</sup>Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined <sup>18</sup>F-Flotufolastat PSMA PET and mpMRI.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Erratum.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Live from 2026 SNMMI Annual Meeting in Los Angeles!

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

CXCR4-based imaging agents.

Lauren E Woodard1, Sridhar Nimmagadda

  • 1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland 21231, USA.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|November 3, 2011
PubMed
Summary
This summary is machine-generated.

Chemokine receptor 4 (CXCR4) and its ligand (CXCL12) drive cancer progression and therapy resistance. CXCR4-based imaging agents offer new avenues for cancer diagnosis and treatment monitoring.

More Related Videos

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis
11:28

Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis

Published on: March 25, 2016

Related Experiment Videos

Last Updated: May 28, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis
11:28

Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis

Published on: March 25, 2016

Area of Science:

  • Oncology
  • Molecular Imaging
  • Drug Development

Background:

  • The chemokine receptor 4 (CXCR4)-chemokine ligand 12 (CXCL12) axis is crucial for cancer cell survival, proliferation, migration, and therapeutic resistance.
  • This axis is implicated in tumor angiogenesis and metastasis, making it a significant target for cancer therapy.
  • Current therapeutic strategies targeting the CXCR4-CXCL12 pathway are advancing, with several inhibitors in early clinical trials.

Purpose of the Study:

  • To review recent advancements in CXCR4-based imaging agents.
  • To explore the potential of these agents in the molecular diagnosis and treatment monitoring of cancer.
  • To highlight the importance of patient stratification and noninvasive monitoring for optimizing CXCR4-targeted therapies.

Main Methods:

  • Review of recent scientific literature on CXCR4-based imaging agents.
  • Analysis of the role of CXCR4 in various cancer hallmarks.
  • Discussion of the clinical development of CXCR4-targeting therapies and imaging agents.

Main Results:

  • Development of novel imaging agents targeting CXCR4.
  • Demonstration of the utility of CXCR4 imaging in identifying cancer patients and monitoring treatment response.
  • Identification of CXCR4 as a biomarker for patient stratification and therapeutic guidance.

Conclusions:

  • CXCR4-based imaging agents represent a promising tool for molecularly diagnosing and monitoring cancer.
  • These agents can aid in patient stratification, potentially improving therapeutic outcomes and reducing toxicity.
  • Further development and clinical validation of CXCR4 imaging agents are essential for their integration into cancer care.